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Abstract
The effect of an antisense oligonucleotide to the Kq channel coding mKv1.1 mRNA on antinociception induced by the tricyclic
Ž y1 . Ž y1 .antidepressants, clomipramine 20–35 mg kg s.c. and amitriptyline 10–25 mg kg s.c. , was investigated in the mouse hot-plate
Ž .test. Antisense oligonucleotide 0.5-1.0-2.0-3.0 nmol per i.c.v. injection produced a dose-dependent inhibition of clomipramine and
amitriptyline antinociception 72 h after the last i.c.v. injection. The sensitivity to both analgesic drugs returned 7 days after antisense
oligonucleotide injection, indicating the absence of irreversible damage or toxicity. Treatment with a degenerated oligonucleotide did not
Ž .modify the clomipramine- and amitriptyline-induced antinociception in comparison with that in naive unpretreated controls , vector and
Ž .saline i.c.v.-injected mice. A quantitative reverse transcription-polymerase chain reaction RT-PCR study demonstrated a reduction in
mRNA levels only in the antisense oligonucleotide treated group. Antisense oligonucleotide, degenerated oligonucleotide or vector
pretreatment, in the range of doses used, did not produce any behavioural impairment as revealed by the mouse rotarod and hole-board
tests. The present results indicate that modulation of the mKv1.1 Kq channel plays an important role in the central analgesia induced by
the tricyclic antidepressants, clomipramine and amitriptyline. q 1997 Elsevier Science B.V.
q Ž .Keywords: Antisense oligonucleotide; K channel; mKv1.1; Analgesia; Antinociception; Clomipramine; Amitriptyline; Tricyclic antidepressant; Mouse
1. Introduction
The tricyclic antidepressants have been used for many
years to suppress certain types of pain in humans. These
types include diabetic neuropathy, postherpetic neuralgia,
headaches, arthritis, chronic back pain, cancer pain, phan-
tom limb pain. Tricyclic antidepressants are also analgesics
Žin laboratory animals Murua and Molina, 1991; Goldstein
.et al., 1990; Acton et al., 1992 . The analgesic effect of
tricyclic antidepressant drugs seems to be independent of
their antidepressant activity since the doses used for anal-
gesia are lower than those considered effective in the
Ž .treatment of depression Acton et al., 1992 .
The serotoninergic neurones of the dorsal raphe nucleus
innervate numerous areas of the brain and spinal cord such
as the hippocampus and the periaqueductal gray neurones
) Ž . Ž .Corresponding author. Tel.: 39-55 423-7432; Fax: 39-55 436-1613;
e-mail: bartolin@stat.ds.unifi.it
Ž .Pazos and Palacios, 1985 , regions involved in a variety
of diverse physiological functions including pain modula-
Ž .tion Besson and Chaouch, 1987 . Clomipramine and
amitriptyline, as well as other tricyclic antidepressants, are
inhibitors of serotonin reuptake. The subsequent increase
of endogenous serotonin in the synaptic cleft is responsible
for the increase in the pain threshold in mice directly
Ž .Galeotti et al., 1995 , or through activation of the opioid
Ž .system Sacerdote et al., 1987 . Furthermore, clomipramine
analgesia has been reported to underlie the activation of a
signal transduction mechanism operated by pertussis
Ž . Žtoxin-sensitive G-proteins G proteins Galeotti et al.,iro
.1996 .
The stimulation of 5-HT receptors can affect several
Kq channels in central neurones as documented in bio-
Žchemical and electrophysiological studies Bobker and
.Williams, 1990 . Neurones possess a wide variety of kinet-
ically distinct Kq channels. Many of these are voltage-de-
Ž .pendent Catterall, 1988; Jan and Jan, 1989 , others can be
modulated by neurotransmitters interacting with G-
0014-2999r97r$17.00 q 1997 Elsevier Science B.V. All rights reserved.
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Žprotein-coupled receptors Brown and Birnbaumer, 1990;
.Brown, 1990 . G proteins can modulate different types of
Kq channels through a direct effect on the ion channel or
through an enzymatic step leading to the generation of
Žcytoplasmic second messengers Brown, 1990; Hille,
.1994 .
Since little is known about the intracellular effectors
involved in the mechanism of action of tricyclic antide-
pressants, we decided to investigate the role of Kq chan-
nels in the clomipramine and amitriptyline enhancement of
the pain threshold. The first mammalian Kq channel genes
Ž .were isolated from mouse brain Tempel et al., 1988 and
Ž .rat brain Baumann et al., 1988 , based on the similarity of
these genes to the Drosophila Shaker Kq channel genes
Ž .Jan and Jan, 1989; Salkoff et al., 1992 . These genes were
designated Kv1.1 to indicate their ionic selectivity, voltage
sensitivity, subfamily membership and order of isolation
Ž .Chandy, 1991 . Functional expression of the mouse Kv1.1
Ž .gene in Xenopus oocytes Hopkins and Tempel, 1992 and
Žin Chinese hamster ovary cells Robertson and Owen,
. Ž .1993 demonstrated that mKv1.1 previously MBK1 gen-
Ž .erates, in contrast to the fast transient currents I elicitedA
by the Shaker transcript injection, rapidly activating out-
Ž . qward currents I , characteristic of delayed rectifier KK
channels. The mKv1.1 Kq channel proteins are widely
Ž .distributed in the central nervous system CNS , including
areas involved in the regulation of pain perception, and are
Ž .able to modulate neuronal function Wang et al., 1994 . A
specific antisense oligodeoxyribonucleotide targeting the
translation start region of the mKv1.1 mRNA was de-
signed. The effect of intracerebroventricular injection of
the antisense oligodeoxyribonucleotide, in comparison with
that of a degenerated oligodeoxyribonucleotide, on the
antinociception induced by the antidepressant drugs,
clomipramine and amitriptyline, was evaluated in mice.
We also investigated whether amitriptyline analgesia,
like clomipramine analgesia, was prevented by intracere-
broventricular administration of pertussis toxin.
2. Materials and methods
2.1. Animals
Ž . ŽMale Swiss albino mice 23–30 g from Morini San
.Polo d’Enza, Italy were used. The mice were housed 15
per cage. The cages were placed in the experimental room
24 h before the test for adaptation. The animals were fed a
standard laboratory diet and tap water ad libitum and kept
at 23"18C with a 12-h lightrdark cycle, light on at 7
a.m.
2.2. Antisense oligonucleotides
Ž .24mer phosphodiester oligonucleotides ODNs were
capped by a terminal phosphorothioate double substitution
and purified by high-performance liquid chromatography
Ž .HPLC; Genosys, The Woodlands, TX, USA . The anti-
Ž Xsense oligonucleotide 5 -CGA CAT CAC CGT CAT GAT
X. XGAA AGC-3 was designed by targeting the 5 portion of
the murine Kv1.1 mRNA, residues 575–598 of the pub-
Ž .lished cDNA sequence Chandy et al., 1990 . A fully
degenerated 24mer oligonucleotide was used as control.
2.3. Administration of antisense oligonucleotide
Mice were randomly assigned to an antisense oligo-
Žnucleotide, degenerated oligonucleotide, vector DOTAP;
w Ž . xN- 1- 2,3-dioleoyloxy propyl -N, N, N-trimethylammonium
.methyl sulfate , saline or naive group. 100, 200, 400 and
600 mM oligonucleotides were preincubated at 378C for 30
min with 13 mM DOTAP. Each group received a single
Ž .intracerebroventricular i.c.v. injection on days 1, 4 and 7.
2.4. Administration of pertussis toxin
ŽMice were randomly assigned to a vehicle water solu-
tion containing 0.01 M sodium phosphate buffer, pH 7.0,
. Žwith 0.05 sodium chloride or a pertussis toxin group 0.25
.mg per mouse . Naive animals did not receive any pretreat-
ment whereas vehicle and pertussis toxin groups received a
Ž .single intracerebroventricular i.c.v. injection on day 1.
2.5. IntracerebroÕentricular injection technique
Ž .Intracerebroventricular i.c.v. administration was per-
formed under ether anaesthesia using isotonic saline as a
solvent, according to the method described by Haley and
Ž .McCormick 1957 . Briefly, during anaesthesia, mice were
grasped firmly by the loose skin behind the head. A 0.4
mm external diameter, hypodermic needle attached to a 10
ml syringe was inserted perpendicularly through the skull
and no more than 2 mm into the brain of the mouse, where
5 ml was then administered. The injection site was 1 mm
to the right or left from the midpoint on a line drawn
through to the anterior base of the ears. Injections were
performed into the right or left ventricle randomly. To
ascertain that the oligonucleotides were administered ex-
actly into the cerebral ventricle, some mice were injected
with 5 ml of 1:10 diluted India ink and their brains were
examined macroscopically after sectioning.
2.6. BehaÕioural tests
2.6.1. Hot plate test
The method adopted was described by O’Callaghan and
Ž .Holtzman 1975 . Mice were placed inside a stainless steel
container, thermostatically set at 52.5"0.18C in a preci-
Žsion water-bath from KW Mechanical Workshop Siena,
. Ž .Italy . Reaction times s , were measured with a stopwatch
before and 15, 30 and 45 min after treatment. The endpoint
used was licking of the forepaws or hind paws. Mice
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scoring below 12 and over 18 s in the pretest were not
Ž .used 30% . An arbitrary cut-off time of 45 s was adopted.
The analgesic effect of amitriptyline on the pertussis
toxin-treated group was evaluated 11 days after pertussis
toxin injection.
Following the above-mentioned pretreatment schedule
with the antisense oligonucleotide, the antinociceptive ef-
fect of clomipramine and amitriptyline was evaluated 72 h
and 7 days after the last i.c.v. injection. The percentage of
the maximum analgesic effect was evaluated as follows:
% of maximum analgesic effect




The hole board test setup utilizes a 40 cm square plane
Ž .with 16 flush-mounted cylindrical holes diameter 3 cm
distributed 4 by 4 in an equidistant, grid-like manner. The
mice were placed in the center of the board one by one and
left to move about freely for a period of 5 min each. Two
photoelectric beams, crossing the plane from mid-point to
mid-point of opposite sides, thus dividing the plane into 4
equal quadrants, automatically signaled the movement of
the animals on the surface of the plane. Miniature photo-
electric cells, in each of the 16 holes, recorded the explo-
Ž .ration of the holes head plunging activity by the mice.
The test was performed 72 h after the last i.c.v. injection of
antisense oligonucleotide, degenerated oligonucleotide or
vector.
2.6.3. Rotarod test
The apparatus consists of a base platform and a rotating
rod of 3 cm diameter with a non-skid surface. The rod was
placed at a height of 15 cm from the base. The rod, 30 cm
in length, was divided into 5 equal sections by 6 disks.
Thus up to 5 mice were tested simultaneously on the
apparatus, with a rod-rotation speed of 16 r.p.m. The
integrity of motor coordination was assessed on the basis
of the number of falls from the rod in 30 s, according to
Ž .Vaught et al. 1985 . Performance time was measured
before and 15, 30 and 45 min after subcutaneous adminis-
tration of saline. The test was performed 72 h after the last
i.c.v. injection of antisense oligonucleotide, degenerated
oligonucleotide or vector.
2.7. In Õitro studies
2.7.1. RT-PCR-based analysis of mKÕ1.1 mRNA
Mouse brain levels of Kv1.1 mRNA were determined
by a quantitative reverse transcription-polymerase chain
Ž . Ž .reaction RT-PCR method Quattrone et al., 1995a,b .
Briefly, 72 h after the last i.c.v. injection of vector,
antisense oligonucleotide or degenerated oligonucleotide,
between 3 and 5 mice per group were killed and their
Ž .brains were rapidly removed and stored y808C . Frozen
Ž .brain samples 0.2–0.3 g w.w. were homogenized in 3
volumes of RNAzol in order to extract total RNA accord-
ing to the manufacturer’s instructions. RNA was treated
with RQ1 RNase-free DNase, purified by ethanol precipi-
tation, dissolved in water containing an RNase inhibitor
Ž .RNasin at 1 urml and reversely transcribed to cDNA
using random hexamers. Kv1.1 amplimers were 5X-GCT
CTC TCC TGG CCT CCT-3X and 5X-GTT TCG AAG
CGC AGC CCG-3X, residues 544–561 and 715–732 re-
spectively, according to the Kv1.1 cDNA published se-
Ž .quence Chandy et al., 1990 . b-Actin was used as internal
standard gene. PCR cycles consisted of 1-min denaturation
at 928C, 1-min annealing at 568C and 1-min extension at
728C for 30 cycles. Amplification products were first
identified by sequencing then quantified by densitometry.
2.8. Reagents and drugs
Oligonucleotides used for the antisense strategy, and
specific primers or hexamers used for RT-PCR analysis
Ž w Ž .were from Genosys. DOTAP N- 1- 2,3-dioleoyloxy pro-
x .pyl -N, N, N-trimethylammonium methyl sulfate was from
Ž .Boehringer-Mannheim Mannheim, Germany . RNAzol
Ž .was from Cynna Biotecx Houston, TX, USA ; RQ1
RNase-free DNase, RNase ONE, RNasin, Mo-MLV re-
verse transcriptase and fmol sequencing kit were from
Ž .Promega Madison, WI, USA ; Taq polymerase was from
Ž .Perkin-Elmer-Cetus Emeryville, CT, USA . The following
Ždrugs were used: clomipramine Anafranil, Ciba Geigy,
. ŽBasel, Switzerland , amitriptyline Sigma, St. Louis, MO,
. Ž . ŽUSA , D-amphetamine De Angeli , pertussis toxin Re-
.search Biochemicals International, Natick, MA, USA .
Analgesic drugs and D-amphetamine were dissolved in
Ž .isotonic NaCl 0.9% saline solution immediately before
use. Antisense and degenerated oligonucleotides were dis-
Ž .solved in the vector DOTAP at least 30 min before
injection. Drug concentrations were prepared in such a
way that the necessary dose could be administered in a
y1 Ž .volume of 10 ml kg by subcutaneous s.c. injection or
5 ml per mouse by i.c.v. injection.
2.9. Sequence and statistical analysis
Sequences of Kv genes were from the GenBank
database. Sequence comparisons of both antisense oligo-
nucleotide and RT-PCR primers with the database were
carried out using the FASTA program. All experimental
results are given as the means"S.E.M. An analysis of
Ž .variance ANOVA , followed by Fisher’s Protected Least
Ž .Significant Difference PLSD procedure for post-hoc
comparison, was used to verify the significance of differ-
ences between two means of behavioural results. Data
were analysed with the StatView software for the Macin-
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Ž .tosh 1992 . The statistical significance of RT-PCR was
obtained using Student’s t-test; P values of less than 0.05
were considered significant.
3. Results
3.1. Design of oligonucleotides
Considering that the translation start sites of mRNAs
are particularly sensitive to antisense oligonucleotide ac-
Ž .tion Goodchild, 1989; Stein and Cheng, 1993 , we com-
pared the sequence of this site to the murine Kv1.1 cDNA
and other known Kq channel coding genes, in order to
design an effective and specific anti-mouse Kv1.1 anti-
sense oligonucleotide. As summarised in Table 1, we
noted that the 24 bp segment 5X-GCT TTC ATC ATG
X ŽACG GTG ATG TCG-3 residues 575–598 of the pub-
.lished mouse Kv1.1 cDNA sequence; Chandy et al., 1990 ,
has a low sequence homology even with the nearest mem-
Žbers of the Shaker-like subfamily 54% with Kv1.2, Kv1.3,
.Kv1.4 and is almost totally unrelated to members of other
Kv gene subfamilies. We therefore designed an antisense
oligonucleotide which is complementary to this Kv1.1
mRNA segment and is most probably unable to target
other mouse Kv mRNAs. Moreover, this antisense oligo-
nucleotide has terminal GCs at both 5X- and 3X-end, known
for enhancing the binding affinity of antisense oligonucleo-
tidermRNA heteroduplexes. Considering the described se-
quence-independent, non-antisense effects of oligonucleo-
Žtides Storey et al., 1991; Gao et al., 1992; Blagosklonny
.and Neckers, 1994; Schick et al., 1995 , we designed a
fully degenerated phosphodiester-phosphorotioate capped
oligonucleotide as the most suitable control for these po-
tentially confusing effects. The fully degenerated 24mer is
a collection of about 3=1014 different molecular species,
so that for the nanomolar-micromolar range concentrations
achieved in in vitro antisense experiments for this degener-
ated control, every species, i.e. every oligonucleotide of
defined sequence, is present at the site of action at a
sub-attomolar concentration which is totally insufficient to
achieve any antisense, or generally sequence-dependent,
cellular effect. Therefore, if oligonucleotide i.c.v. adminis-
tration per se had yielded any biological response, this
would have been present in degenerated oligonucleotide-
treated controls.
3.2. Effect of pertussis toxin on amitriptyline antinocicep-
tion
Pertussis toxin, administered at the dose of 0.25 mg per
mouse i.c.v. 11 days prior to the test, led to a loss of the
Ž y1 .antinociceptive effect of amitriptyline 20 mg kg s.c. .
This antagonism was revealed by using the hot-plate test
as shown in Table 2.
3.3. Effect of antisense oligonucleotide on clomipramine
and amitriptyline antinociception
The effects produced by the antisense oligonucleotide to
Ž y1 .the mKv1.1 gene on clomipramine 20–35 mg kg s.c.
Ž y1 .and amitriptyline 10–25 mg kg s.c. analgesia were
evaluated by using the mouse hot-plate test.
72 h after pretreatment with antisense oligonucleotide
Ž .0.5 nmol per i.c.v. injection the mice had no statistically
Ž y1significant reduction in clomipramine 25 mg kg s.c.;
. Ž y1 .Fig. 1A and amitriptyline 20 mg kg s.c.; Fig. 2A
analgesia compared with vector and degenerated oligo-
nucleotide treated groups. On the other hand, at the dose of
1.0 and 2.0 nmol per i.c.v. injection, the antisense oligo-
nucleotide dose dependently prevented the analgesic effect
Ž .of clomipramine Fig. 1B and C and, at the dose of 1.0
and 3.0 nmol per i.c.v. injection, dose dependently reduced
Ž .amitriptyline antinociception Fig. 2B and C . These ant-
Table 1
Homology of aODN-targeted sequence in mouse Kv1.1 mRNA both with other genes of the Shaker-like subfamily and with Kv genes of other subfamilies
Ž .translation start codons are underlined; base identity are bold
Gene target Sequence % homology Acc. number
Kv1.1 GCUUUCAUCAUGACGGUGAUGUCG M30439
Shaker-related
Kv1.2 GCCCCAAUUAUGACAGUGGCUACC 54 M30440
Kv1.3 CCGCCAGACAUGACCGUGGUGCCC 54 M30441
Kv1.4 ACCACCACCAUGGAGGUGGCGAUG 54 U03723
Kv1.5 CCCCGGACCAUGGAGAUCUCCCUG 33 L22218
Kv1.7 CGAGGUGACAUGAGAUCGGAGAAA 29 M96688
Shab-related
Kv2.1b GGCGCCGCGAUGGGCCAAGGGGAC 25 L48983
Shaw-related
Kv3.1 GGCGCCGCGAUGGGCCAAGGGGAC 25 Y07521
Kv3.3 GCGGUGGCCAUGGGGCGGCACGGC 37 X60796
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Table 2
Ž .Effect of pertussis toxin PTX pretreatment on amitriptyline-induced antinociception in the mouse hot-plate test
Ž .Pretreatment Treatment Licking latency s
Before treatment After treatment
15 min 30 min 45 min
Vehicle Saline 15.9"0.8 15.2"0.7 15.0"0.9 14.4"0.8
Vehicle Amitriptyline 14.2"0.4 25.2"1.2 29.2"2.5 20.7"2.0
PTX 0.25 mg Saline 14.5"1.2 13.4"1.1 13.3"1.3 13.7"1.3
b b aPTX 0.25 mg Amitriptyline 14.2"0.7 15.7"1.2 15.0"1.3 14.4"1.2
Ž . Ž y1 .The test was performed 11 days after a single i.c.v. injection of vehicle or pertussis toxin 0.25 mg per mouse . Saline and amitriptyline 20 mg kg were
administered s.c.; values are means"S.E.M.; there were 8–22 mice per group. a P-0.05, b P-0.01 in comparison with vehicle-amitriptyline-treated
mice.
Ž y1 .Fig. 1. Prevention of clomipramine 25 mg kg s.c. -induced antinoci-
Ž .ception by pretreatment with an antisense ODN aODN to mKv1.1 gene
in the mouse hot-plate test. Mice were i.c.v. injected with vector,
Ž . Ž .antisense ODN or degenerated ODN dODN at the dose of 0.5 A , 1.0
Ž . Ž .B and 2.0 nmol per injection C on days 1,4 and 7. The hot-plate test
was performed 72 h after the last i.c.v. injection. Vertical lines give
S.E.M.; there were 10–17 mice per group. ) P -0.05, ) ) P -0.01 in
comparison with degenerated ODNqclomipramine-treated mice.
Ž y1 .Fig. 2. Prevention of amitriptyline 20 mg kg s.c. -induced antinoci-
Ž .ception by pretreatment with an antisense ODN aODN to mKv1.1 gene
in the mouse hot-plate test. Mice were i.c.v. injected with vector,
Ž . Ž .antisense ODN or degenerated ODN dODN at the dose of 0.5 A , 1.0
Ž . Ž .B and 3.0 nmol per injection C on days 1, 4 and 7. The hot-plate test
was performed 72 h after the last i.c.v. injection. Vertical lines give
S.E.M.; there were 9–17 mice per group. ) P -0.05 in comparison with
degenerated ODNqamitriptyline treated mice.
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Ž .Fig. 3. Effect of increasing concentrations of an antisense ODN aODN
Ž y1 . Ž .to the mKv1.1 gene on clomipramine- 25 mg kg s.c. A and
Ž y1 . Ž .amitriptyline- 20 mg kg s.c. B induced antinociception in the
mouse hot-plate test. Mice received a single i.c.v. injection of antisense
Ž .ODN 0.5-1.0-2.0-3.0 nmol per injection on days 1, 4 and 7. The
hot-plate test was performed 72 h after the last i.c.v. injection. The
analgesic effect was detected 30 min after clomipramine and amitriptyline
administration. Each point represents the mean for at least 10 mice.
agonistic effects were detected 72 h after the end of the
antisense oligonucleotide pretreatment. The pretreatment
with the degenerated oligonucleotide never modified
clomipramine and amitriptyline induced antinociception in
comparison with vector i.c.v.-injected mice as shown in
Figs. 1 and 2, respectively.
The dose-dependent inhibition of clomipramine and
amitriptyline antinociception produced by increasing con-
centrations of antisense oligonucleotide is shown in Fig.
3A and B, respectively. The percentage of the maximum
analgesic effect corresponded with the maximum effect of
clomipramine and amitriptyline occurring 30 min after
administration.
Ž y1 .Both clomipramine 20–35 mg kg s.c. and
Ž y1 .amitriptyline 10–25 mg kg s.c. produced dose-depen-
Ž .dent antinociception Fig. 4 . In order to restrict the obser-
vation to the range of doses of clomipramine and
amitriptyline with analgesic activity and devoid of other
behavioral effects, we tested clomipramine and amitripty-
Žline at doses that did not impair motor coordination data
.not shown . Pretreatment with antisense oligonucleotide
Ž .1.0–3.0 nmol per i.c.v. injection prevented the antinoci-
ception induced by increasing concentrations of
Ž . Žclomipramine Fig. 4, panel A and amitriptyline Fig. 4,
.panel B to different degrees depending on the dose of
analgesic drug that displaced to the right the clomipramine
Ž . Ž .panel A and amitriptyline panel B dose-response line.
The licking latency values reported in Fig. 4 were evalu-
ated in relation to the maximum analgesic effect of
Žclomipramine and amitriptyline 30 min after administra-
.tion .
The prevention of clomipramine and amitriptyline anal-
gesia produced by antisense oligonucleotide at, respec-
tively, 2.0 nmol and 3.0 nmol per i.c.v. injection, disap-
peared 7 days after the end of the antisense oligonucleotide
Ž .pretreatment Fig. 5 .
The antisense oligonucleotide pretreatment did not re-
duce the pain threshold in mice, having no hyperalgesic
Ž . Ž .effect at both 72 h Figs. 1 and 2 and 7 days Fig. 5 after
the last i.c.v. injection of antisense oligonucleotide.
Repeated i.c.v. injections of vector or saline did not
modify the sensitivity of animals to the analgesic treat-
Ž .Fig. 4. Effect of i.c.v. pretreatment with an antisense ODN aODN to
Ž .mKv1.1 gene or degenerated ODN dODN on the antinociceptive effect
Ž y1produced by increasing concentrations of clomipramine 20–35 mg kg
. Ž y1 .s.c., panel A and amitriptyline 10–25 mg kg s.c., panel B in the
mouse hot-plate test. Mice received a single i.c.v. injection of aODN or
Ž . Ž .dODN at the dose of 1.0 nmol panel A or 3.0 nmol panel B per
injection on days 1, 4 and 7. The hot-plate test was performed 72 h after
the last i.c.v. injection. The evaluation of the analgesic effect was carried
out 30 min after administration of clomipramine and amitriptyline. Verti-
cal lines give S.E.M.; each point represents the mean for at leas 9 mice.
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Table 3
Ž .Comparison between vector DOTAP and saline pretreatment on clomipramine- and amitriptyline-induced antinociception in the mouse hot-plate test
Ž .Pretreatment Treatment Licking latency in mice s
y1nmol per mouse mg kg Before treatment After treatment
i.c.v. s.c. 15 min 30 min 45 min
Vector Saline 16.0"1.8 14.8"1.0 15.0"1.0 14.6"0.7
Saline Saline 15.9"1.6 14.1"1.0 14.7"1.1 14.3"0.9
– Saline 14.2"0.9 14.2"1.1 15.6"0.8 15.1"0.9
a b aVector Clomipramine 25 15.0"1.8 19.4"1.4 23.3"1.5 19.0"1.7
b b aSaline Clomipramine 25 15.4"1.4 22.6"2.9 24.0"3.6 19.6"2.8
b c b– Clomipramine 25 15.0"0.9 19.8"1.4 24.5"2.3 20.5"1.3
c c cVector Amitriptyline 20 14.3"0.8 26.4"2.0 33.9"3.6 27.9"1.5
c c cSaline Amitriptyline 20 12.2"0.4 25.2"1.2 30.2"2.5 24.7"2.0
c c b– Amitriptyline 20 13.0"0.6 26.7"0.9 29.6"1.7 24.6"1.9
Ž .Mice were injected i.c.v. on days 1, 4 and 7 with saline or vector. Non-pretreated naive animals did not receive any i.c.v. injection. The experiment was
performed 72 h after the last i.c.v. injection. There were 8–21 mice per group. a P-0.01, b P-0.01, c P-0.001 versus corresponding control mice.
Ž .ments in comparison with that of unpretreated naive mice
Ž .Table 3 .
3.4. Effect of antisense oligonucleotide on mouse be-
haÕiour
The motor coordination of mice pretreated with anti-
Ž .sense oligonucleotide 2.0 nmol per injection or degener-
Ž .Fig. 5. Lack of effect of an antisense ODN aODN to the mKv1.1 gene
Ž . Ž y1on the tricyclic antidepressant drugs TCA clomipramine 25 mg kg
. Ž y1 .s.c. and amitriptyline 20 mg kg s.c. induced antinociception 7 days
after the end of the antisense ODN treatment. Mice were injected with
Ž .vector, antisense ODN or degenerated ODN dODN at the dose of 2.0 or
3.0 nmol per injection on days 1, 4 and 7. Modification of the pain
threshold was evaluated by using the mouse hot-plate test. The licking
latency was detected 30 min after clomipramine or amitriptyline adminis-
tration. Vertical lines give S.E.M.; there were 9–12 mice per group.
) P -0.01, ) ) P -0.001 in comparison with saline-treated mice.
Ž .ated oligonucleotide 2.0 nmol per injection was evaluated
by using the rotarod test 72 h after the last i.c.v. injection.
The motor coordination of both antisense oligonucleotide-
and degenerated oligonucleotide-treated groups was not
impaired when compared with that of vector-treated mice,
since each group progressively reduced its number of falls
Ž .Table 4 , because mice learned how to balance on the
rotating rod.
The spontaneous motility and inspection activity of
mice were not modified by pretreatment with antisense
Ž .oligonucleotide 2.0 nmol per injection or degenerated
Ž .oligonucleotide 2.0 nmol per injection , in comparison
with vector-treated mice, as revealed by the hole-board test
Ž .Fig. 6 . The test was performed 72 h after the end of the
antisense oligonucleotide pretreatment. Under the same
Ž y1 .experimental conditions D-amphetamine 1 mg kg s.c. ,
used as a reference drug, increased both motility and
Ž .inspection activity Fig. 6 .
3.5. Effect of antisense oligonucleotide on specific inhibi-
tion of mKÕ1.1 gene expression
The lowering of Kv1.1 mRNA following antisense
oligonucleotide administration as an index of Kv1.1 gene
Table 4
Ž .Lack of effect of repeated i.c.v. injections of an antisense ODN aODN
to mKv1.1 gene in the mouse rotarod test
Number of falls in 30 s
Pretest After s.c. saline injection
15 min 30 min 45 min
Vector 4.9"0.6 3.9"0.9 3.0"1.0 2.6"1.1
aODN 2 nmol 5.9"0.4 5.1"0.6 4.0"0.8 3.1"0.8
dODN 2 nmol 5.0"0.8 3.8"0.6 3.2"0.5 3.0"0.5
ŽMice were i.c.v. injected with vector, antisense ODN 2.0 nmol per
. Ž . Ž .injection or degenerated ODN dODN 2.0 nmol per injection on days
1, 4 and 7. The rotarod test was performed 72 h after the last i.c.v.
injection. There were 10 mice per group.
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Fig. 6. Lack of effect of repeated i.c.v. injections of an antisense ODN
Ž .aODN to mKv1.1 gene in the mouse hole-board test in comparison with
Ž y1 .D-amphetamine 1 mg kg s.c. used as reference drug. Mice were
Ž .injected with vector, antisense ODN 2.0 nmol per injection or degener-
Ž . Ž .ated ODN dODN 2.0 nmol per injection on days 1, 4 and 7. The
hole-board test was performed 72 h after the last i.c.v. injection. D-
Amphetamine was injected 15 min before the test. Vertical lines give
S.E.M.; the number of mice is shown in parentheses. ) P -0.05 in
comparison with vector-treated mice.
inactivation was quantified by RT-PCR. The quantitative
results for Kv1.1 mRNA brain levels following antisense
oligonucleotide treatment confirmed that the blockade of
clomipramine- and amitriptyline-induced antinociception is
Žassociated with the specific Kv1.1 mRNA lowering Fig.
.7 .
Fig. 7. Quantitative RT-PCR analysis of mKv1.1 mRNA. Following
Ž . Ž .antisense ODN aODN or degenerated ODN dODN treatment, total
RNA was extracted from the brains of behaviourally tested mice. mKv1.1
and b-actin mRNA were submitted to RT-PCR as reported in Section 2.
Amplification products were analysed on agarose gel and quantified by
densitometry. Within the linearity of PCR, the amount of mKv1.1 mRNA
relative to b-actin mRNA was calculated. Data are the means of three
determinations. Vertical lines represent S.E.M.
4. Discussion
Repeated i.c.v. administration of an antisense targeted
to mKv1.1, a Shaker-like Kq channel, inhibits the analge-
sia induced by the tricyclic antidepressant drugs
clomipramine and amitriptyline. Under our experimental
conditions, the antisense oligonucleotide treatment did not
modify the gross behaviour of mice. The motor coordina-
tion, spontaneous motility and inspection activity of mice
pretreated with the antisense oligonucleotide were not
impaired in comparison with those of groups treated with
degenerated oligonucleotide and vector making the results
obtained in the hot-plate test reliable. Moreover, the inhibi-
tion of tricyclic antidepressant analgesia by anti-mKv1.1
antisense disappeared 7 days after the last i.c.v. injection,
indicating a lack of irreversible damage or toxicity on
cerebral structures caused by the antisense oligonucleotide.
Pretreatment with the anti-mKv1.1 antisense did not
modify the pain threshold, showing the absence of any
hyperalgesic effect. Therefore, the prevention of
clomipramine and amitriptyline antinociception cannot be
attributable to a direct effect on the pain threshold induced
by the antisense oligonucleotide. Furthermore, the degen-
erated oligonucleotide did not antagonise clomipramine-
and amitriptyline-induced antinociception in comparison
with naive or saline- and vector-i.c.v. injected mice. This
observation ruled out the possibility that the antagonism
exerted by antisense oligonucleotide may have resulted
from a sequence-independent action on cerebral structures.
This hypothesis was further supported by results of a
quantitative RT-PCR study demonstrating a reduction in
mKv1.1 mRNA levels only on the antisense oligonucleo-
tide-treated group.
The present results not only indicated an important role
of mKv1.1 in the mechanism of analgesic action of
clomipramine and amitriptyline, but also confirmed the
usefulness of antisense strategies for in vivo investigations.
Antisense oligonucleotides have proved to be useful phar-
macological tools for exploring biological processes in the
Ž .central nervous system CNS both in vitro and in vivo
ŽChung et al., 1995; Standifer et al., 1994; Rossi et al.,
.1994; Zhang et al., 1994; Wahlestedt, 1994 . Antisense
oligonucleotides specifically bind to targeted mRNA, pre-
venting translation andror mediating mRNA cleavage by
RNase H and, thus, down-regulate the synthesis of the
encoded protein. Low cell permeability and the marked
degradation of natural phosphodiester oligomers are con-
siderable drawbacks in the application of antisense oligo-
nucleotides both in vitro and in vivo. In order to overcome
these drawbacks, phosphorothioate-capped phosphorodi-
ester oligonucleotides, a class of oligonucleotide deriva-
tives that has been shown to maintain more stable and
effective concentrations in the brain when compared to
Ž .their unmodified counterpart Whitesell et al., 1993 , were
used. Furthermore, both oligonucleotide stability and cell
uptake have been enhanced by associating oligonucleotides
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Ž .with an artificial cationic lipid DOTAP used as an intra-
Žcellular carrier Capaccioli et al., 1993; Quattrone et al.,
.1994 .
We investigated the involvement of mKv1.1 in the
analgesia induced by clomipramine and amitriptyline since
mKv1.1 Kq channels seem to play an important role in
regulating neuronal function. The mKv1.1 channel is
Žwidely expressed in mouse brain Adams et al., 1991;
.Wang et al., 1994 including areas involved in the regula-
tion of the pain threshold. Moreover, mKv1.1 plays a
prominent role in the hippocampus where it seems to be
involved in the regulation of membrane repolarization and
Žin the duration or amount of neurotransmitter release Wang
.et al., 1994 .
Little is known about the turnover of the protein Kv1.1
in mouse brain. Results of longer pulse-chase experiments
with mouse L-cells indicate that Kv1.1 degradation has a
Ž .t of approximately 5 h Deal et al., 1994 . However it1r2
has to be noted that, in L-cells, cell surface channels are
represented by two molecular mass species, 57 and 59
kDa, while the Kv1.1 channel in mouse brain appears as a
Ž .single 80 kDa species Wang et al., 1993 . It is, therefore,
difficult to extend the data obtained in L-cells to the mouse
brain because it is possible that this differential processing
between the L-cell system and brain has functionally sig-
nificant consequences.
The administration schedule of antisense oligonucleo-
Žtide a single i.c.v. injection every 72 h for a total of 3
.injections was chosen on the basis of in vivo antinocicep-
tion experiments reported in the literature in which a
minimum treatment time of 3–5 days seems necessary to
achieve inhibition of neurotransmitter receptor synthesis
ŽRossi et al., 1994; Chien et al., 1994; Chen et al., 1995;
Standifer et al., 1994; Tseng and Collins, 1994; Tseng et
.al., 1994 . Furthermore, the Kv1.1 mRNA levels were
Ž .reduced 48 h after treatment data not shown and a
maximal lowering was reached at 72 h. The validity of the
treatment schedule used was further supported by the
evidence that, after a single intrathecal injection, antisense
oligonucleotide accumulates within the spinal cord and
Ž .remains stable for at least 72 h Standifer et al., 1995 .
The treatment with the antisense oligonucleotide to the
mKv1.1 gene prevented the antinociception induced by
clomipramine and amitriptyline, indicating the involve-
ment of the Shaker-like voltage-gated Kq channels in the
enhancement of the pain threshold produced by the activa-
tion of the serotoninergic system. In fact, clomipramine
and amitriptyline analgesia implies an enhancement of
serotonin levels in the synaptic cleft. The intracellular
mechanism of analgesic action of clomipramine and
amitriptyline involves the activation of a pertussis toxin-
Žsensitive G-protein, since not only clomipramine Galeotti
.et al., 1996 but also amitriptyline analgesia is prevented
by the i.c.v. administration of pertussis toxin. Pertussis
toxin-sensitive G-proteins represent the most widespread
Žmodulatory signalling pathway in neurones Holz et al.,
.1986 and are responsible for modulation of ionic conduc-
tance andror lowering of intracellular cyclic AMP levels
ŽBrown and Birnbaumer, 1990; Hepler and Gilman, 1992;
.Hille, 1994 . Physiological evidence suggests that
voltage-gated Kq channels can also be modulated by
neurotransmitters and hormones in many tissues. Indeed,
protein kinase A modulation of delayed rectifier-type Kq
currents has been shown in the heart and in lymphocytes
Ž .Giles et al., 1989; Soliven and Nelson, 1990 . More
recently an increase in mKv1.1 Kq channel expression at
the levels of RNA, protein and current density in Chinese
hamster ovary cells was found as a result of reduced basal
Ž .protein kinase A activity Bosma et al., 1993 . Serotonin
has both excitatory and inhibitory actions in the CNS since
it can interact with a large number of 5-HT receptor
subtypes coupled to different second messenger systems
such as adenylate cyclase, and is able to modulate different
q Žion channels, such as some K channels Zifa and Fillion,
.1992; Lucas and Hen, 1995 . Since clomipramine and
amitriptyline analgesia is mediated by the serotoninergic
system with the involvement of a pertussis toxin-sensitive
G-protein, and mKv1.1 function is regulated by protein
kinase A levels, the mKv1.1 Kq channel might be in-
volved in tricyclic antidepressant-induced analgesia as an
intracellular effector underlying the activation of a Giro
protein.
In conclusion, the present data demonstrate that mKv1.1
Kq channels are an important step in the transduction
mechanism underlying central antinociception induced by
clomipramine and amitriptyline.
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